Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02143726
Recruitment Status : Active, not recruiting
First Posted : May 21, 2014
Last Update Posted : October 12, 2020
Sponsor:
Collaborators:
National Cancer Institute (NCI)
Novartis
Information provided by (Responsible Party):
Alliance for Clinical Trials in Oncology

Brief Summary:
This randomized phase II trial studies the effects, good and bad, of using everolimus along with sorafenib tosylate versus sorafenib tosylate alone in treating patients with advanced radioactive iodine refractory thyroid cancer. Sorafenib tosylate and everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. The addition of everolimus to sorafenib tosylate may cause more shrinkage of thyroid cancer and may prevent it from growing but it could also cause more side effects than sorafenib tosylate alone. It is not yet known whether this treatment with sorafenib tosylate and everolimus is better, the same, or worse than sorafenib tosylate alone.

Condition or disease Intervention/treatment Phase
Refractory Hurthle Cell Thyroid Cancer Drug: sorafenib Drug: everolimus Phase 2

Detailed Description:

This randomized Phase II trial will compare the progression-free survival (PFS) of sorafenib and everolimus versus sorafenib alone in patients with radioactive iodine refractory hurthle cell thyroid cancer. Prior studies have shown that the median PFS is generally around 4.5 months for sorafenib alone in this disease population. It is hoped that the combination of everolimus and sorafenib can increase the median PFS to at least 9 months. In addition to PFS, this trial will also compare the confirmed response rate, overall survival (OS) and adverse event rates between sorafenib and everolimus vs. sorafenib alone. The primary and secondary objectives for the study are listed below.

Primary Objective:

To compare the progression free survival between sorafenib and everolimus versus sorafenib alone in patients with radioactive iodine refractory Hurthle cell thyroid cancer

Secondary Objective:

To compare the confirmed response rate, overall survival and adverse event rates between sorafenib and everolimus versus sorafenib alone.

Treatment will continue until disease progression or unacceptable adverse events. Patients will be followed for 5 years after randomization.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 35 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Randomized Phase II Study of Sorafenib With or Without Everolimus in Patients With Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer
Study Start Date : October 2014
Estimated Primary Completion Date : August 2021


Arm Intervention/treatment
Active Comparator: sorafenib
Patients receive sorafenib 400 mg PO twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with progressive disease may cross over and receive everolimus 10 mg PO once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Drug: sorafenib
Given PO
Other Name: Nexavar ®, BAY 43-9006

Experimental: sorafenib and everolimus
Patients receive sorafenib 400 mg PO twice daily and everolimus 5 mg PO once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Drug: sorafenib
Given PO
Other Name: Nexavar ®, BAY 43-9006

Drug: everolimus
Given PO
Other Name: RAD001, Afinitor ®




Primary Outcome Measures :
  1. Progression Free Survival [ Time Frame: Up to 5 years post-randomization ]

Secondary Outcome Measures :
  1. Confirmed response rate [ Time Frame: Up to 5 years post-randomization ]
  2. Overall survival [ Time Frame: Up to 5 years post-randomization ]
  3. Incidence of adverse events, graded according to Common Terminology Criteria for Adverse Events [ Time Frame: Up to 5 years post-randomization ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Eligibility Criteria:

  1. Central pathology review submission - Patients must have 10 representative hematoxylin and eosin (H&E) stained thyroid tissue slides OR tumor block available for submission to central pathology review. This review is mandatory prior to registration to confirm eligibility.
  2. Measurable disease - Patients must have measurable disease by Response Evaluation Criteria In Solid Tumors (RECIST) criteria, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as ≥ 20 mm with conventional techniques or as ≥ 10 mm with spiral computed tomography (CT) scan. CT must be performed within 28 days of registration.
  3. Radioactive iodine (RAI) - refractory disease defined as 1 or more of the following:

    • Patients who have received greater than 600 mCi of radioactive iodine in their lifetime OR
    • RAI-avid metastatic lesion which remained stable in size or progressed despite RAI treatment within 9 months of RAI treatment OR
    • 10% or more increase in serum thyroglobulin (on thyroid-stimulating hormone [TSH]-suppression) within 9 months of RAI treatment OR
    • Index metastatic lesion non-RAI avid on a diagnostic RAI scan OR
    • Presence of fluorodeoxyglucose (FDG) avid metastatic lesions on positron emission tomography (PET)/CT scan (standardized uptake values [SUV]max > 5 of any single lesion)
  4. Progressive disease defined by RECIST criteria ≤ 14 months
  5. Patients must have metastatic disease or locally advanced unresectable disease
  6. Prior treatment

    • Patients may have received prior radiation therapy to index lesions ≥ 28 days prior to registration on this protocol if there has been documented progression by RECIST criteria. Prior radiation therapy to the non-index lesions is allowed if ≥ 28 days prior to registration on this protocol.
    • Prior RAI therapy is allowed if ≥ 90 days prior to registration on this protocol and evidence of progression (as defined above) has been documented in the interim (a diagnostic study using < 10 mCi of RAI is not considered RAI therapy).
    • Prior chemotherapy is allowed if ≥ 28 days prior to registration on this protocol.
    • Patient may have received any number of prior lines of therapy.
    • No prior use of sorafenib or an mammalian target of rapamycin (mTOR) (including phosphoinositide 3-kinase [PI3k] or protein kinase B [AKT]) inhibitor for the treatment of thyroid cancer.
  7. No history of major surgery ≤ 28 days of registration
  8. No history of intracranial brain metastasis
  9. Cardiovascular disease. No history of any of the following ≤ 6 months of registration:

    • Myocardial infarction or unstable angina
    • New York Heart Association grade III or greater congestive heart failure
    • Cerebrovascular accident
    • Grade 3 or 4 peripheral ischemia
    • Grade 3 or 4 thromboembolic event
  10. Liver disease: No history of the following:

    • Child Pugh Class B or C liver disease
    • "Chronic active" hepatitis defined as:

      1. Hepatitis B surface antigen (HBsAg) > 6 months
      2. Serum hepatitis B virus (HBV) deoxyribonucleic acid (DNA) 20,000 IU/ml (105 copies/ml), lower values 2,000-20,000 IU/ml (104-105 copies/ml) are often seen in hepatitis B e antigen (HBeAg)-negative chronic hepatitis B
      3. Persistent or intermittent elevation in alanine aminotransferase (ALT)/aspartate aminotransferase (AST) levels
      4. Liver biopsy showing chronic hepatitis with moderate or severe necroinflammation
  11. No history of gastrointestinal fistula or gastrointestinal perforation < 90 days of registration.
  12. No known history of prolonged QT syndrome
  13. No Grade 3 or 4 hypertension (systolic blood pressure [BP] >160 and or diastolic BP > 100) that cannot be controlled with medication prior to registration.
  14. Concomitant medications:

    • Chronic concomitant treatment with strong inhibitors of cytochrome P450 3A4 (CYP3A4) is not allowed on this study. Patients on strong CYP3A4 inhibitors must discontinue the drug for 14 days prior to registration on the study.
    • Chronic concomitant treatment with strong CYP3A4 inducers is not allowed. Patients must discontinue the drug 14 days prior to the start of study treatment.
    • Patients requiring anticoagulation must be on stable dose of medication prior to registration.
  15. Not pregnant and not nursing, because this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown. Therefore, for women of childbearing potential only, a negative serum pregnancy test done ≤ 7 days prior to registration is required.
  16. Age ≥ 18 years
  17. Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2
  18. Required Initial Laboratory Values:

    • Absolute neutrophil count (ANC) ≥ 1,500/mm^3
    • Platelet count ≥ 100,000/mm^3
    • Creatinine ≤ 1.5 mg/dL OR
    • Calculated creatinine clearance ≥ 30 mL/min
    • Total bilirubin ≤ 1.5 x upper limits of normal (ULN)
    • Serum glutamic oxaloacetic transaminase (SGOT) (AST) ≤ 2.5 x ULN
    • Fasting serum cholesterol ≤ 300 mg/dL
  19. Documentation of disease: Histologic Documentation - Eligible patients must have histopathologically confirmed Hürthle cell thyroid cancer by central review.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02143726


Locations
Show Show 21 study locations
Sponsors and Collaborators
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)
Novartis
Investigators
Layout table for investigator information
Study Chair: Eric Sherman, M.D. Memorial Sloan Kettering Cancer Center
Layout table for additonal information
Responsible Party: Alliance for Clinical Trials in Oncology
ClinicalTrials.gov Identifier: NCT02143726    
Other Study ID Numbers: A091302
U10CA180821 ( U.S. NIH Grant/Contract )
NCI-2014-00623 ( Registry Identifier: NCI Clinical Trials Reporting Office )
First Posted: May 21, 2014    Key Record Dates
Last Update Posted: October 12, 2020
Last Verified: October 2020
Additional relevant MeSH terms:
Layout table for MeSH terms
Thyroid Neoplasms
Thyroid Diseases
Endocrine System Diseases
Endocrine Gland Neoplasms
Neoplasms by Site
Neoplasms
Head and Neck Neoplasms
Everolimus
Sorafenib
Antineoplastic Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action